Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

Dow Jones

03/27

0753 GMT - Novartis's proposed acquisition of Excellergy for up to $2 billion strengthens its immunology pipeline and, while investors don't know what the current cash outflow is, payments should be back-end loaded, Vontobel's Stefan Schneider says in a research note. The deal mainly targets a drug candidate that is designed to overcome the fundamental limitations of existing therapies and could allow for broader use across food allergies, chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma and other diseases, Vontobel says. Considering this is a new treatment approach and Excellergy's lead asset is in early-stage trials, the Swiss pharmaceutical company's payments should be back-end loaded, the analyst says. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 27, 2026 03:54 ET (07:54 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2622984501"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622984501\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622984501?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 15:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622984501","market":"nz","top_or_hot":-1,"title":"Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0753 GMT - Novartis's proposed acquisition of Excellergy for up to $2 billion strengthens its immunology pipeline and, while investors don't know what the current cash outflow is, payments should be back-end loaded, Vontobel's Stefan Schneider says in a research note. The deal mainly targets a drug candidate that is designed to overcome the fundamental limitations of existing therapies and could allow for broader use across food allergies, chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma and other diseases, Vontobel says. Considering this is a new treatment approach and Excellergy's lead asset is in early-stage trials, the Swiss pharmaceutical company's payments should be back-end loaded, the analyst says. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2026 03:54 ET (07:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-27 15:54</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0753 GMT - Novartis's proposed acquisition of Excellergy for up to $2 billion strengthens its immunology pipeline and, while investors don't know what the current cash outflow is, payments should be back-end loaded, Vontobel's Stefan Schneider says in a research note. The deal mainly targets a drug candidate that is designed to overcome the fundamental limitations of existing therapies and could allow for broader use across food allergies, chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma and other diseases, Vontobel says. Considering this is a new treatment approach and Excellergy's lead asset is in early-stage trials, the Swiss pharmaceutical company's payments should be back-end loaded, the analyst says. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2026 03:54 ET (07:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"駿利亨德森環球生命科技A Acc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622984501","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622984501","pubTimestamp":1774598040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0753 GMT - Novartis's proposed acquisition of Excellergy for up to $2 billion strengthens its immunology pipeline and, while investors don't know what the current cash outflow is, payments should be back-end loaded, Vontobel's Stefan Schneider says in a research note. The deal mainly targets a drug candidate that is designed to overcome the fundamental limitations of existing therapies and could allow for broader use across food allergies, chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma and other diseases, Vontobel says. Considering this is a new treatment approach and Excellergy's lead asset is in early-stage trials, the Swiss pharmaceutical company's payments should be back-end loaded, the analyst says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4588":"碎股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4578":"CAR-T","BK4585":"ETF&股票定投概念","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","NVS":"诺华","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4532":"文艺复兴科技持仓","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4007":"制药","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC"},"translate_title":"诺华的Excellergy付款应在后端加载——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"0753 GMT - Novartis's proposed acquisition of Excellergy for up to $2 billion strengthens its immunology pipeline and, while investors don't know what the current cash outflow is, payments should be back-end loaded, Vontobel's Stefan Schneider says in a research note. The deal mainly targets a drug candidate that is designed to overcome the fundamental limitations of existing therapies and could allow for broader use across food allergies, chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma and other diseases, Vontobel says. Considering this is a new treatment approach and Excellergy's lead asset is in early-stage trials, the Swiss pharmaceutical company's payments should be back-end loaded, the analyst says. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 03:54 ET (07:54 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}